Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
1.96 USD 0.00% Intraday chart for VYNE Therapeutics Inc. +8.29% -15.88%
02:00pm VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development CI
Jul. 01 VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index CI

Evolution of the average Target Price on VYNE Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

060a0a7444a7038.Lj7KxUM23F_YNIIlJ7kK8z-4Y6afQGc9OYpUCG44WSA.e1f6tjNlpSfsfLcUQ_BNwlzLEdfHD0pfDsJlZl4LKmlYW4b0dWCFELF_tg~61c4b7834a24a28fbbafc3478b9e097d

Analyst Recommendations on VYNE Therapeutics Inc.

Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating MT
HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating MT
HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target MT
VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating MT
VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating MT
VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.96 USD
Average target price
5.583 USD
Spread / Average Target
+184.86%
High Price Target
6 USD
Spread / Highest target
+206.12%
Low Price Target
5 USD
Spread / Lowest Target
+155.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering VYNE Therapeutics Inc.

Cantor Fitzgerald
HC Wainwright
Northland Securities

Ratings for VYNE Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. Consensus VYNE Therapeutics Inc.